Current Health Receives FDA Clearance for its Remote Patient Monitoring Solution, Enables Earlier Intervention and Improved Patient Outcomes

The company will demonstrate its wireless wearable, which monitors
vital signs with ICU-level accuracy and delivers patient-specific alerts
and treatment recommendations, at HIMSS19

NEW YORK & EDINBURGH, Scotland–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/AI?src=hash” target=”_blank”gt;#AIlt;/agt;–Current
Health
, an artificial intelligence (AI)-powered wearable, today
announced it has received Class II clearance from the U.S. Food and Drug
Administration (FDA) for hospital care. Current is a wireless device
that continuously and automatically monitors patients to help better
determine health trajectory and allows clinicians to intervene earlier.

Faced with an aging
population
and strained healthcare systems worldwide, U.S. and U.K.
healthcare providers are deploying Current to change their patient
delivery models from reactive to proactive care to produce better
patient outcomes. Current’s approach will help health organizations
reduce unnecessary hospital readmissions for patients whose conditions
deteriorate after treatment — an expensive and cumbersome clinical
burden that costs U.S. hospitals more than $40
billion annually
.

Mount Sinai Brooklyn is working with Current to detect patient
deterioration earlier and improve healthcare outcomes, resulting in the
safest and highest quality care for patients. Dr. Scott Lorin, president
of Mount Sinai Brooklyn, said: “The Mount Sinai Health System works with
innovative and leading-edge companies like Current to support our
commitment to providing world-class patient care. Current’s continuous
and proactive monitoring platform has the potential to alert us to
patient deterioration faster and give our team data insights they can
act on earlier.”

Built using the world’s largest real-time physiological data set,
Current is the most accurate, all-in-one wireless wearable currently
approved for use in the EU and U.S. The company’s proprietary algorithms
continuously analyze data, along with relevant contextual patient
information, to offer actionable and proactive insights into the
wearer’s health. It seamlessly integrates with third-party devices to
capture additional metrics, building patient-specific digital
therapeutics and recommendations.

Current is actively in use with U.K. healthcare providers in a
post-acute setting, including Dartford and Gravesham NHS Trust, which
serves a local population of 500,000 people. The Dartford
and Gravesham NHS Trust
Hospital at Home team uses Current to
remotely monitor patients after discharge. As a result, clinicians and
staff reprioritized home visits based on criticality, resulting in a 22
percent reduction in home visits and fewer hospital readmissions and
emergency department visits, which freed up skilled nursing time and
helped patients feel safe and secure.

“At Current, we’re a small team of individuals committed to changing the
world through proactive healthcare,” said Christopher McCann, CEO of
Current. “Our team worked hard to get here, and it’s just the first step
toward monitoring the health of every human being to identify sickness
earlier with the goal of saving lives. Today, we’re in the hospital,
tomorrow the home, and in the near future, we’ll be everywhere. We are
just getting started.”

Current is demonstrating its FDA-cleared solution at the HIMSS19 trade
show in Orlando from February 11 to 14 at Booth 5359-05. Additionally,
CEO Christopher McCann is presenting a talk titled, “Deriving
actionable insights from RPM and telehealth”
on Wednesday, February
13, at 12:45 p.m. ET at the Healthcare of the Future Pavilion #5359.

Founded in 2014, Current is headquartered in Edinburgh, Scotland with an
office in New York. The team is led by co-founders Christopher McCann
and Stewart Whiting, and is comprised of Ph.D.s, clinical researchers,
healthcare professionals, data scientists and engineering experts.

For more information, contact:

About Current Health
Current Health (formerly snap40) is the
most accurate, all-in-one wireless wearable currently approved in the
U.S. and EU. The company’s proprietary algorithms continuously analyze
data, along with relevant contextual patient information, to offer
actionable and proactive insights into the wearer’s health. Current’s
FDA-cleared wearable monitors the human body with ICU-level accuracy
across more vital signs than any other all-in-one device on the market.
Headquartered in Edinburgh, Scotland, with an office in New York,
Current is venture backed by investors ADV, MMC Ventures and others. For
more information, visit https://www.currenthealth.com/.

Contacts

Metis Communications
Caroline Curran, 910-409-4126
current@metiscomm.com